Loading...
Market
Will Neffy nasal spray surpass Epi-Pen in market share by August 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share reports from reputable market research firms or sales data from ARS Pharmaceuticals
Story
FDA Approves Purdue and ARS Pharmaceuticals' Treatments for Overdoses and Allergies
Aug 9, 2024, 02:16 AM
Purdue Pharma has received approval from the U.S. Food and Drug Administration (FDA) for a new nalmefene hydrochloride auto-injector. This device is designed for the emergency treatment of known or suspected opioid overdoses in adults and pediatric patients aged 12 and older. The approval is part of the FDA's ongoing efforts to broaden access to opioid overdose reversal agents. Additionally, the FDA approved ARS Pharmaceuticals' nasal spray, Neffy, as the first needle-free emergency treatment for potentially fatal allergic reactions, including life-threatening anaphylaxis. Neffy, which contains epinephrine, offers a non-injection alternative to the Epi-Pen, potentially saving lives.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0 countries • 25%
1 to 3 countries • 25%
4 to 6 countries • 25%
More than 6 countries • 25%